Today: 1 February 2026
Subscribe
Browse Category

EPA:ABVX News 16 December 2025 - 22 December 2025

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire In early market action, multiple outlets reported…
22 December 2025
·······
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

December 16, 2025 — ABIVAX Société Anonyme (listed as ABVX on Euronext Paris and Nasdaq) is back in the spotlight today after publishing third-quarter 2025 financial results and reiterating a long cash runway—news that didn’t stop the stock from pulling back as investors digested widening losses and the sheer scale of the rally already priced in. In U.S. trading, Abivax’s…
16 December 2025
·····

Stock Market Today

  • Alkane Resources Shares Soar 177% in 12 Months Despite EPS Decline
    February 1, 2026, 5:42 PM EST. Alkane Resources Ltd (ASX:ALK) investors have seen a 177% return over the past year, with the stock also rising 63% in the last quarter. However, this surge occurred despite a 30% drop in earnings per share (EPS). The company's revenue grew by 82% year-on-year, suggesting that top-line growth, rather than profit, has been driving the share price. Insiders have been buying shares recently, indicating management confidence. Over three years, the stock has risen 139%, reflecting long-term positive sentiment. Analysts remain cautious, pointing to the need to monitor future earnings and potential risks. Alkane's recent rally may signal business momentum, but investors should consider multiple factors beyond share price performance before making decisions.
Go toTop